TG Therapeutics Q2 BRIUMVI Revenue Hits $228M, Refinances Debt with $750M Term Loan
TGTX sits 100% above its 52-week low of $25.28.
Summary
TG Therapeutics reported Q2 2026 BRIUMVI U.S. revenue of $227.7M (+64% YoY), raised full-year guidance to ~$950M, refinanced debt with a $750M term loan, and announced positive clinical data for next-generation BRIUMVI formulations.
Key Events · Earnings and Guidance · TGTX
-
BRIUMVI Revenue Surges 64%
Q2 2026 BRIUMVI U.S. net product revenue reached $227.7 million, up from $138.8 million in Q2 2025, driven by strong market penetration. Total revenue was $240.3 million, with net income of $7.8 million.
-
Full-Year Guidance Raised to ~$950M
Management raised full-year 2026 total revenue guidance to approximately $950 million, reflecting confidence in continued BRIUMVI growth and ex-U.S. royalties.
-
$750M Term Loan Refinancing
The company replaced its $250 million term loan with a new $750 million facility maturing in 2031, improving liquidity and extending debt maturity. A $9.2 million loss on extinguishment was recorded in Q1 2026.
-
Share Repurchase Program Expanded to $300M
The board increased the share repurchase authorization from $100 million to $300 million. Through June 30, 2026, $100 million of stock had been repurchased at an average price of $30.44 per share.
Analysis · TGTX · Life Sciences
TG Therapeutics delivered strong Q2 2026 results with BRIUMVI U.S. net revenue of $227.7 million, up 64% year-over-year, and raised full-year guidance to approximately $950 million. The company refinanced its $250 million term loan with a larger $750 million facility, extending maturity to 2031 and providing ample liquidity. Positive clinical data for a single-infusion BRIUMVI regimen and subcutaneous formulation support lifecycle management, while a $300 million share repurchase authorization signals confidence. The combination of accelerating commercial execution, pipeline progress, and a strengthened balance sheet makes this a highly important update for investors.
At the time of this filing, TGTX was trading at $50.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $25.28 to $59.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.